In 2005, Adrienne learned she had Lynch syndrome, an inherited genetic mutation that significantly increased her risk for several types of cancer. Eight years later, she was diagnosed with metastatic ampullary cancer. She underwent 13 months of chemotherapy, which did not work. When genetic testing of Adrienne’s tumor showed it was microsatellite instability-high (MSI-H), her oncologist recommended she enroll in a clinical trial for pembrolizumab (Keytruda®). Just over two months later, the cancer was gone. She continued to receive treatment for two years, traveling from her home in New York to Johns Hopkins in Baltimore. Over two years since her last treatment, she remains cancer-free and has returned to her busy life working, spending time with her four daughters, practicing yoga, playing tennis, and traveling with friends and family.
UPDATE, December 2019: Adrienne remains cancer-free and spoke at the CRI Immunotherapy Patient Summit in Baltimore on November 16, 2019.
Provide guidance and encouragement to others going through their journey with cancer immunotherapy treatment.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.
Cancer is not “one-size-fits-all” and neither are its treatments, especially when it comes to immunotherapy. Learn how CRI is helping more people overcome cancer.